LUND, Sweden, July 31, 2019 /PRNewswire/ -- BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces that Pfizer Inc. ("Pfizer") (NYSE: PFE) has selected the first target under the companies' cancer immunotherapy research collaboration and license

ROCKVILLE, Md., July 31, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today announced it entered into a license agreement with Pfizer Inc.Under the terms of the agreement, REGENXBI

DUBLIN, July 31, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the second quarter ended June 30, 2019. Revenue for the second quarter of 2019 was $26.2 million. Second quarter operating loss was

MDNA19 demonstrates robust efficacy and safety with or without checkpoint inhibitors in preclinical models; Clinical studies expected to commence in 2020 TORONTO and HOUSTON, July 31, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.  ("Medicenna" or "the Company") (TSX: MDNA, OTCQB:

PRINCETON, N.J., July 31, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that two posters outlining ongoing formulation efforts to develop a trivalent thermostabil

Partnership Facilitated by Major Investment from Arsenal Capital Partners NEW YORK, July 31, 2019 /PRNewswire/ -- Caprion Biosciences ("Caprion") and HistoGeneX announced today they have agreed to combine their respective businesses. The new partnership creates a global leader in immune monitoring, protein characterization, and tissue pathology solutions f

WALTHAM, Mass., July 31, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2019 financial results on Wednesday, August 7, after the clo

MISGAV, Israel, July 31, 2019 /PRNewswire/ -- MetoMotion, a portfolio company of The Trendlines Group Ltd. (SGX: 42T) (OTCQX: TRNLY), announced that it has completed an investment round of $1.5 mill

REHOVOT, Israel, July 31, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today its financial results for the second quarter ending June 30, 2019.

LOS ANGELES, July 31, 2019 /PRNewswire/ -- Bio-Up Mimetic Technologies Inc., a biotechnology company that invented a patent-pending